Our Capabilities

PPF Group has a vision to build a diversified biotech portfolio of innovative therapies in oncology. Since 2012, PPF has continued to build upon its presence in the biotechnology sector and successfully completed several deals, adding promising assets to its pipeline. With more than 350 employees across its portfolio of biotech companies, PPF has built a strong team with the expertise required for successful development of novel therapies.

Highlights of the PPF biotechnology capabilities

Global footprint:

The biotechnology presence of PPF includes the United States, Europe, China and Russia. SOTIO is currently conducting a global Phase III clinical trial in the United States and Europe as well as multiple Phase II oncology studies in selected EU countries. SOTIO also initiated SC103, a first-in-human Phase I clinical trial with SO-C101 program developed originally by Cytune Pharma. Multiple pre-clinical projects in the PPF portfolio are advancing through preclinical development to enter the clinic soon.

Financial strength:

PPF Group is one of the largest investment groups in Central and Eastern Europe, investing across multiple industries including biotechnology, with total assets exceeding EUR 47 billion (as at 30 June 2019).

Focus on partnerships:

PPF is currently building its biotech portfolio and seeks to add new innovative oncology therapies to its pipeline, with SOTIO leading this effort. PPF and SOTIO are providing expertise and financial resources to each partnership and asset.

Current portfolio:

To date, PPF has added to its pipeline novel therapeutic projects of SOTIO, Cytune Pharma, and Lead Discovery Center. PPF has also established research collaboration with NBE Therapeutics, invested into Cytune Pharma, NBE Therapeutics and Cellestia, and acquired Accord Research, a clinical CRO. For more information please visit PPF/SOTIO Biotech Pipeline and PPF Biotech Ventures sections.

Areas of expertise:

PPF has built an integrated development expertise, including in-house research, early & late stage clinical development and operations capabilities, GMP facilities for manufacturing personalized cellular immunotherapies, regulatory expertise, global logistics, financial and commercial planning, which can be leveraged through partnerships.

This website uses cookies; by continuing to use this page, you consent to their use. About cookies